NYSE:ROIV

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
······

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE shares rose 0.7% to $803.67 Wednesday, trailing biotech peers after Immunovant reported positive rheumatoid arthritis trial data for IMVT-1402, sending its stock up 35.1%. VYVGART sales reached $1.3 billion last quarter. The FDA recently expanded VYVGART’s approval for generalized myasthenia gravis. argenx’s next key data releases are expected later this year.
May 20, 2026

Stock Market Today

  • ASX Investors Face Hidden Overexposure to US 'Magnificent 7' Tech Giants
    May 29, 2026, 8:06 PM EDT. Many Australian investors may unknowingly hold significant stakes in the US tech giants known as the 'Magnificent 7'-Microsoft, Amazon, Alphabet, Meta Platforms, Apple, Tesla, and NVIDIA. These companies dominate various US exchange-traded funds (ETFs) like BetaShares Nasdaq 100 (NDQ), Schwab U.S. Large-Cap Growth (SCHG), iShares S&P 500 (IVV), and others widely held in Australia. In addition, large positions in listed investment companies (LICs) such as MFF Capital and ETFs like VanEck Morningstar Wide Moat (MOAT) further increase exposure. Superannuation funds also typically include these stocks, amplifying collective investment risk. Investors should audit their portfolios to understand the extent of their indirect and direct holdings in these tech behemoths amid their growing market dominance.